Annexin Q2: RVO readout closing in - Redeye

Redeye comments on Annexin's Q2 report and recent events in the company. We note that interest in Annexin has increased rapidly lately following a strong outcome in the rights issue and upcoming phase II topline data in RVO with its drug candidate ANXV - and we expect an eventful summer/autumn ahead for the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/1023996/annexin-q2-rvo-readout-closing-in?utm_source=finwire&utm_medium=RSS